Twentyfour Ambulatory Pulse Wave Velocity and Central Augmentation Index in Type 2 Diabetes

This study has been completed.
Sponsor:
Collaborator:
Regionshospitalet Silkeborg
Information provided by (Responsible Party):
University of Aarhus
ClinicalTrials.gov Identifier:
NCT01812811
First received: March 14, 2013
Last updated: December 10, 2013
Last verified: December 2013

March 14, 2013
December 10, 2013
September 2012
July 2013   (final data collection date for primary outcome measure)
Fraction of missed pulse wave analysis [ Time Frame: Meaured two times with an interval of one week ] [ Designated as safety issue: No ]
Measurements of ambulatory blood pressure and pulse wave analysis is performed every twenty minute. The fraction of missed measurements of pulse wave analysis during day time and night time analysis is the final outcome
Same as current
Complete list of historical versions of study NCT01812811 on ClinicalTrials.gov Archive Site
Reproducibility of pulse wave analysis parameters [ Time Frame: Measured two times with an interval of one week ] [ Designated as safety issue: No ]
Reproducibility of pulse wave velocity, Central systolic blood pressure and central augmentation index for 24 hour, day and night
Reproducibility of pulse wave analysis parameters [ Time Frame: Measured two times with an interval of one week ] [ Designated as safety issue: No ]
Reproducibility of pulse wave velocity, Central systoloc blood pressure and central augmentation index for 24 hour, day and night
Diurnal variation of brachial blood pressure, central blood pressure and pulse wave velocity [ Time Frame: Measured two times with an interval of one week ] [ Designated as safety issue: No ]
brachial blood pressure, central blood pressure and pulse wava velocity is measured evrey twenty minutes and averaged for day time and night time. the relative reduction at nioght for the parameters are calculated
Same as current
 
Twentyfour Ambulatory Pulse Wave Velocity and Central Augmentation Index in Type 2 Diabetes
Twentyfour Ambulatory Pulse Wave Velocity and Central Augmentation Index in Type 2 Diabetes

The functionality and reproducibility of pulse wave analysis is investigated in 20 type 2 diabetic patients who had two 24 hour measurements performed within one week with the Arteriograph24 equipment.

Arteriograph24 is a new monitor for measuring ambulatory blood pressure and additional performing brachial cuff based on analysis of a suprasystolic pulse wave.

The study aim to test the feasibility of ambulatory pulse wave analysis every twenty minute (the fraction of missed measurements)and the reprodicility of pulse wave velocity and central augmentation index in type 2 diabetic patients. In addition we will explore the relation between diurnal variation of brachial blood pressure, central blood pressure and pulse wave velocity.

20 type 2 diabetic patients will have 24h ambulatory blood pressure performed twice with an interval of one week.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Type 2 diabetes patients recruited from out patient clinic

Type 2 Diabetes
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
22
July 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 2 diabetes

Exclusion Criteria:

  • Atrial fibrillation
Both
30 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT01812811
35522
No
University of Aarhus
University of Aarhus
Regionshospitalet Silkeborg
Principal Investigator: Klavs W Hansen, MD, dr.med. Medical department, Diagnostic Center, Regional Hospital Silkeborg, Denmark
University of Aarhus
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP